New drug cocktail aims to wipe out HER2 breast cancer before surgery
NCT ID NCT07635342
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a combination of targeted drugs (pyrotinib and trastuzumab) plus chemotherapy can completely eliminate HER2-positive breast cancer before surgery. About 182 women with early-stage disease will receive 8 cycles of treatment. The main goal is to see if no cancer remains in the breast or lymph nodes after treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pyrotinib, trastuzumab, pegylated liposomal doxorubicin, cyclophosphamide, paclitaxel
What this could lead to
If successful, this combination could become a standard pre-surgery treatment to eliminate HER2-positive breast cancer before surgery, potentially improving long-term outcomes.
What could go wrong
This is a Phase 2 trial with only 182 participants, so results are preliminary. The drug combination may cause side effects like heart problems or severe infections, and may not work for everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Fourth Hospital of Hebei Medical University
RECRUITINGShijiazhuang, Hebei, 050000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••